Skip to main content

Moderna vs Pfizer: Founders, CEOs and History

Moderna was founded in 2010 by Derrick Rossi, Robert Langer, Noubar Afeyan and is led by Stéphane Bancel. Pfizer was founded in 1849 by Charles Pfizer, Charles Erhart and is led by Albert Bourla.

Company facts

Moderna

Founded
2010
Headquarters
Cambridge, Massachusetts, United States
Current CEO
Stéphane Bancel
Employees
4,700

Pfizer

Founded
1849
Headquarters
New York, New York
Current CEO
Albert Bourla
Employees
75,000

Founders

Moderna

  • Derrick Rossi

    Rossi's discovery gave Moderna its name, from 'modified RNA'. He served on the company's early scientific advisory board but did not run it; Stéphane Bancel was recruited as CEO in 2011.

  • Robert Langer

    Robert Langer has served on Moderna's board of directors since its founding and has been instrumental in guiding the company's scientific strategy and partnerships.

  • Noubar Afeyan

    Noubar Afeyan has served as Moderna's chairman since its founding and has been the architect of the company's strategic vision and capital structure.

  • Kenneth Chien

    Chien's work on modified mRNA encoding VEGF-A for heart repair underpinned Moderna's early cardiovascular collaboration with AstraZeneca.

Moderna founders in full

Pfizer

  • Charles Pfizer

    Pfizer possesses a historic, immigrant founding story, rooted entirely in the rapid industrial expansion of 19th-century Brooklyn and defined by an effective, intensely meticulous German chemist and his ambitious confectioner cousin.

  • Charles Erhart

    Charles Erhart's role in Pfizer's founding is less celebrated than his cousin's, partly because the company carries Charles Pfizer's name and partly because his commercial contributions were less visible than the scientific achievements that drove the company'…

Pfizer founders in full

CEOs and their tenures

Moderna

  1. Noubar Afeyan2010–present

    Co-Founder & Chairman

    Has served as Chairman of the Board of Directors since inception, providing venture financing, governance, and long-term capital strategy that helped build Moderna from a startup laboratory into a public biotechnology enterprise.

    Source
  2. Stéphane Bancel2011–present

    Chief Executive Officer (first CEO)

    Bancel has led Moderna from a pre-revenue startup to a $180 billion market cap at its peak, overseeing the development of Spikevax in record time and the company's transition to a multi-product biotechnology enterprise.

    Source
  3. Stephen Hoge2012–present

    President

    Serves as President directing preclinical research, clinical development, and platform innovation, leading the advancement of Moderna's pipeline from an early research concept into five commercialized vaccines and multiple late-stage Phase 3 oncology candidate…

    Source
  4. Jamey Mock2022–present

    Chief Financial Officer

    Oversees global finance, treasury, accounting, and investor relations, navigating Moderna through post-pandemic revenue contraction while managing cash reserves of $8.1 billion in cash and investments at the end of FY2025.

    Source
Moderna CEO history in full

Pfizer

  1. Ian Read2010–2018

    Chief Executive Officer

    He ruthlessly cut R&D spending and eliminated tens of thousands of jobs, significantly boosting short-term earnings per share despite massive patent cliffs for blockbuster drugs like Lipitor.

    Source
  2. Albert Bourla2019–present

    Chairman and Chief Executive Officer

    A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.

    Source
  3. Dave Denton2022–2026

    Chief Financial Officer

    As CFO, he aggressively restructured the balance sheet following the Seagen acquisition, prioritizing debt reduction while defending the dividend.

    Source
  4. Chris Boshoff2025–present

    Chief Scientific Officer and President, Research & Development

    He completely restructured the research and development organization to focus on antibody-drug conjugates (ADCs), aggressively expanding Pfizer's pipeline of cancer therapeutics.

    Source
  5. Cecile Guegan2026–present

    Interim Chief Financial Officer

    She modernized the company's internal auditing and compliance structures, ensuring rapid but safe clinical execution for high-priority vaccine programs.

    Source
Pfizer CEO history in full

Timeline: Moderna and Pfizer side by side

  1. 1849Pfizer

    Pfizer Founded

    Charles Pfizer and Charles Erhart founded the company in Brooklyn.

  2. 1944Pfizer

    Penicillin Scale-Up

    Pfizer helped industrialize penicillin production during World War II.

  3. 1998Pfizer

    Viagra Approved

    The FDA approved Viagra in 1998.

  4. 2000Pfizer

    Warner-Lambert Deal

    Pfizer acquired Warner-Lambert, adding Lipitor.

  5. 2005Moderna

    Karikó and Weissman Publish Modified mRNA Research

    Katalin Karikó and Drew Weissman at the University of Pennsylvania publish foundational research demonstrating that modified nucleosides in mRNA can evade the body's inflammatory response, solving the key obstacle preventing mRNA therapeutics from clinical app…

  6. 2009Pfizer

    Wyeth Acquired

    Pfizer bought Wyeth in 2009 for about $68 billion.

  7. 2010Moderna

    Moderna Therapeutics Founded in Cambridge

    Derrick Rossi, Robert Langer, Noubar Afeyan, Kenneth Chien, and Timothy Springer found Moderna Therapeutics in September 2010, with Flagship Pioneering providing seed funding and incubation.

  8. 2011Moderna

    Stéphane Bancel Appointed Founding CEO

    Stéphane Bancel, former CEO of bioMérieux and executive at Eli Lilly, joins Moderna as founding CEO, bringing pharmaceutical commercial experience to the scientific founding team.

  9. 2012Moderna

    Moderna Emerges from Stealth with $40M Series A

    Moderna emerges from two years of stealth operation with a $40 million Series A financing, revealing its mRNA platform technology to the public for the first time.

  10. 2013Moderna

    AstraZeneca mRNA Collaboration

    Moderna signs a collaboration with AstraZeneca in March 2013 including a $240 million upfront payment to discover and develop mRNA therapeutics for cardiovascular, metabolic, renal and cancer targets, before any Moderna drug had been tested in humans.

  11. 2016Moderna

    Merck Partnership for Personalized Cancer Vaccines

    Moderna and Merck agree in 2016 to co-develop personalized mRNA cancer vaccines combined with Keytruda, the collaboration behind mRNA-4157 (later named intismeran autogene).

  12. 2018Moderna

    Moderna Completes $604 Million IPO

    Moderna lists on Nasdaq in December 2018, raising about $604 million at a valuation of roughly $7.5 billion, one of the largest biotech IPOs at the time.

  13. 2019Pfizer

    Albert Bourla becomes CEO

    Albert Bourla became CEO of Pfizer in 2019. A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.

  14. 2020Moderna

    COVID-19 Vaccine Development in Record Time

    Moderna selects mRNA-1273 as its COVID-19 vaccine candidate on January 13, 2020, just two days after the SARS-CoV-2 sequence was published.

  15. 2020Pfizer

    BioNTech COVID Vaccine Partnership

    Pfizer and BioNTech brought Comirnaty through emergency authorization.

  16. 2021Moderna

    COVID-19 Vaccine Revenue Reaches $18.5 Billion

    Moderna reports 2021 revenue of $18.5 billion and net income of $12.2 billion, almost entirely from its COVID-19 vaccine, its first year of profitability.

  17. 2022Moderna

    Revenue Peaks at $19.3 Billion

    Moderna reports 2022 revenue of $19.3 billion and net income of $8.4 billion, the high point of pandemic sales, as Spikevax is approved and sold under commercial contracts.

  18. 2023Moderna

    Revenue Falls to $6.8 Billion

    Revenue drops to $6.8 billion in 2023 as COVID vaccination turns seasonal, and Moderna posts a $4.7 billion net loss including write-downs tied to excess manufacturing commitments.

  19. 2023Pfizer

    Seagen Acquisition

    Pfizer completed the $43 billion Seagen acquisition.

  20. 2024Moderna

    mRESVIA Approved for RSV Prevention

    The FDA approves mRESVIA (mRNA-1345) in May 2024 for RSV prevention in adults 60 and older, Moderna's first non-COVID product.

  21. 2025Moderna

    Revenue Falls to $1.9 Billion as Costs Are Cut

    Moderna reports 2025 revenue of $1.94 billion and a $2.82 billion net loss, while cutting operating expenses by about $2.2 billion.

  22. 2025Moderna

    CMV Vaccine Fails Phase 3 Primary Endpoint

    Moderna says in October 2025 that its cytomegalovirus vaccine mRNA-1647 failed its Phase 3 primary endpoint and discontinues the congenital CMV program.

  23. 2025Pfizer

    Chris Boshoff Becomes CSO

    Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.

  24. 2025Pfizer

    Metsera Acquisition

    Pfizer completed its acquisition of obesity drug developer Metsera in November 2025 for up to about $10 billion including CVRs.

  25. 2025Pfizer

    FY2025 Revenue Base

    Pfizer reported $62.579 billion of FY2025 revenue.

  26. 2026Moderna

    FDA Approves mFLUSIVA, First mRNA Flu Vaccine

    After an initial FDA refusal-to-file letter early in 2026 was resolved, the FDA approves mFLUSIVA (mRNA-1010) on August 5, 2026 for adults 50 and older, full approval for ages 50-64 and accelerated approval for 65 and older.

  27. 2026Moderna

    Intismeran Autogene Meets Phase 3 Melanoma Endpoint

    On August 19, 2026 Merck and Moderna report that intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival in the Phase 3 INTerpath-001 trial in resected stage IIB-…

  28. 2026Pfizer

    Innovent Oncology Collaboration

    Pfizer signed a 12-program cancer collaboration with Innovent Biologics: $650 million upfront and up to $9.85 billion in milestones.

Acquisitions

Moderna

  • OriCiro Genomics2023$85M
  • Immatics T-Cell Receptor Collaboration IP2023$120M
  • Norwood mRNA Clinical Manufacturing Facility2018$110M
All Moderna acquisitions

Pfizer

  • Metsera, Inc.2025$7B
  • Seagen Inc.2023$43B
  • Medivation Inc.2016$14B
  • Wyeth2009$68B
  • Pharmacia Corporation2003$60B
  • Warner-Lambert Company2000$111B
All Pfizer acquisitions

Questions about Moderna vs Pfizer

Who is the CEO of Moderna, Inc. and Pfizer Inc.?

Moderna, Inc. is led by Stéphane Bancel and Pfizer Inc. is led by Albert Bourla. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was Moderna, Inc. founded vs Pfizer Inc.?

Pfizer Inc. was founded in 1849 — 161 years before Moderna, Inc., which was founded in 2010. Pfizer Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Moderna, Inc..

How many employees does Moderna, Inc. have compared to Pfizer Inc.?

Moderna, Inc. employs approximately 4,700 people, while Pfizer Inc. employs approximately 75,000. Pfizer Inc. has the larger workforce at 75,000 employees, compared to Moderna, Inc.'s 4,700. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are Moderna, Inc. and Pfizer Inc. headquartered?

Both Moderna, Inc. and Pfizer Inc. are headquartered in United States. Their local rules and tax obligations may still differ.

Who founded Moderna, Inc. and Pfizer Inc.?

Moderna, Inc. was founded by Derrick Rossi, Robert Langer, Noubar Afeyan, Kenneth Chien. Pfizer Inc. was founded by Charles Pfizer, Charles Erhart.

Which company has a longer operating history — Moderna, Inc. or Pfizer Inc.?

Pfizer Inc. has been operating for approximately 177 years, making it the more established of the two companies. Moderna, Inc. has been in operation for around 16 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Moderna vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.